3 terminated, 2 completed, 1 active not recruiting, 1 unknown. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 3, Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Carcinoma, Large Cell: new trials by email Literature Review of Carcinoma, Large Cell trials Research Report on Carcinoma, Large Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| THIO Sequenced With Cemiplimab in Advanced NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Maia Biotechnology | 227 | 2022-06-08 | 2026-09-16 |
| Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy) - Non-small-cell Lung Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 21 | 2012-08-01 | 2017-12-07 |
| A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 226 | 2011-05-01 | 2014-05-19 |
| A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment Docetaxel, Oxaliplatin - Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous | Phase 2 | Unknown | Korean South West Oncology Group | 35 | 2011-02-01 | 2011-12-22 |
| Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) Temozolomide - Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 53 | 2008-03-04 | 2017-06-07 |
| Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer Motexafin gadolinium and pemetrexed - Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | Pharmacyclics LLC. | 74 | 2006-06-01 | 2013-10-31 |
| Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 54 | 2003-11-01 | 2020-05-28 |
Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Squamous Cell (7) · Adenocarcinoma (3) · Lung Neoplasms (3) · Adenocarcinoma of Lung (2) · Carcinoma (1) · Recurrence (1)
Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Squamous Cell (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Carcinoma (6) · Lung Neoplasms (4) · Adenocarcinoma (2) · Disease Attributes (1)
Docetaxel (2) · Oxaliplatin (1) · Pemetrexed (1) · Radiosurgery (1) · Radiotherapy (1) · Temozolomide (1) · alpha-2'-deoxythioguanosine (1) · cemiplimab (1) · motexafin gadolinium (1) · tanespimycin (1)
Infinity Pharmaceuticals, Inc. (1) · Korean South West Oncology Group (1) · M.D. Anderson Cancer Center (1) · Maia Biotechnology (1) · Merck Sharp & Dohme LLC (1) · NewLink Genetics Corporation (1) · Pharmacyclics LLC. (1)
United States (5) · Hungary (2) · South Korea (2) · Taiwan (2) · Australia (1) · Bulgaria (1) · Georgia (1) · Poland (1) · Romania (1) · Russia (1) · Turkey (Türkiye) (1)
Arun Rajan, M.D. (1) · Joe Y. Chang, MD, MS, PHD (1) · Martin Edelman, MD (1) · Sang Byung Bae, M.D. (1) · Tess Schmalbach, MD (1) · Victor Zaporojan, MD (1)
2023 (1), P01CA021239 (1)